ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

IMRN Immuron Ltd

2.52
-0.02 (-0.79%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Immuron Ltd IMRN NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.02 -0.79% 2.52 23:00:11
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.62 2.4815 2.62 2.52 2.54
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/5/202405:00GLOBEImmuron Director Resignation
15/4/202405:00GLOBEImmuron to host Live Virtual Event
10/4/202405:00GLOBEImmuron Travelan® sales continued strong growth
07/3/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202405:00GLOBEImmuron Announces Positive Results Support Travelan®..
28/2/202407:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/2/202405:00GLOBEImmuron Presentation Australian Biologics Festival 2024
13/2/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/2/202405:00GLOBEImmuron achieves record Travelan® sales
08/2/202405:00GLOBEImmuron CEO, Steven Lydeamore Investor Webinar Presentation
16/1/202407:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/1/202405:00GLOBEImmuron achieves record half yearly Travelan® sales
22/12/202306:21EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/12/202305:00GLOBEImmuron Clinical Trials Update
04/12/202305:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/12/202305:00GLOBEImmuron Announces First Patients Enrolled in Campylobacter..
28/11/202305:33GLOBEImmuron CEO, Steven Lydeamore Investor Webinar Presentation
28/11/202305:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/11/202306:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/202317:00GLOBEImmuron CEO Steven Lydeamore Investor Webinar Presentation
13/11/202307:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/10/202306:21GLOBEImmuron CEO Steven Lydeamore presented at AusBioInvest
23/10/202307:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/10/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/10/202305:00GLOBEImmuron Announces Travelan® Clinical Study Cohort 2..
11/10/202305:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/10/202305:00GLOBEImmuron achieves record quarterly Travelan® sales
28/9/202307:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/9/202305:18EDGAR2Form 20-F - Annual and transition report of foreign private..
13/9/202305:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202305:00GLOBEImmuron achieves record monthly Travelan® sales
11/9/202305:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202305:00GLOBEImmuron CEO, Steven Lydeamore to present at H.C. Wainwright
30/8/202305:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202305:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202305:00GLOBEImmuron to present at the Military Health System Research..
09/8/202305:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/7/202305:00GLOBEImmuron Announces First Patients Enrolled in Travelan®..
24/7/202320:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202305:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/7/202305:00GLOBEImmuron CEO, Steven Lydeamore to present at Bioshares
11/7/202305:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202305:00GLOBEImmuron Business Update - Ateria Health launches Juvia™ in..
05/7/202305:00GLOBEImmuron FY23 Sales increase 136% on FY22 Sales
30/6/202305:08EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/6/202305:00GLOBEImmuron Chairman Transition
22/6/202305:00GLOBEImmuron Business Update: Letter to Shareholders

Su Consulta Reciente

Delayed Upgrade Clock